SSY Group (HKG:2005) said its Morinidazole has received registration approval from China's National Medical Products Administration as a bulk drug for preparations already on the market, according to a Tuesday Hong Kong bourse filing.
Morinidazole, a nitroimidazole antibiotic, is mainly used to treat appendicitis and pelvic inflammatory disease caused by anaerobic bacteria, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.